NCT05147467 2026-03-27
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
Clinical Trials
6 trialsNCT07272499 2025-12-09
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
Phase 2 Recruiting
NCT07255963 2025-12-01
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06389292 2025-11-25
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT04496349 2025-11-04
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT04501120 2025-09-26
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting